Novartis Q3 profit up 25% on strong drug sales, guidance reaffirmed
PositiveFinancial Markets

Novartis has reported a remarkable 25% increase in profits for the third quarter, driven by robust sales of its pharmaceuticals. This strong performance not only highlights the company's effective product lineup but also reinforces its guidance for future growth. Investors and stakeholders can feel optimistic as Novartis continues to demonstrate resilience and success in a competitive market.
— Curated by the World Pulse Now AI Editorial System











